• Evotec

  • Luis de la Osa de la Rosa

Luis de la Osa de la Rosa

Senior Research Assistant at Evotec

Luis de la Osa de la Rosa is a seasoned professional in laboratory and research settings, currently serving as a Senior Research Assistant at Evotec since January 2023. Prior experience includes roles as a Biological Research Technician at Deutsches Herzzentrum München from April 2020 to June 2022, where responsibilities involved working in the Experimental Surgery research department under Dr. Stefanie Doppler, and as a Research Laboratory Technician at Ludwig-Maximilians-Universität (LMU) München from February 2013 to March 2020, contributing to the organic chemistry department under Prof. Dr. Luis also completed an Erasmus Internship as a Microbiology Technician at Latis Scientific in 2012, focusing on media preparation and sample processing. Luis holds a Certificate of Higher Education as a Senior Technician in Analysis and Quality Control in the Laboratory, obtained from CPIFP Corona de Aragón in Zaragoza, Spain, in 2012.

Links


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


Evotec

5 followers

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.


Industries

Headquarters

Hamburg, Germany

Employees

1,001-5,000

Links